Skip to main content

Advertisement

Table 2 Details of included monotherapy RCTs*

From: Network meta-analysis combining individual patient and aggregate data from a mixture of study designs with an application to pulmonary arterial hypertension

Reference Badesch 2002 Rubin 2002 (BREATHE-1) Barst 2006 (STRIDE-2) Barst 1996 Galie 2005 (SUPER-1)
Baseline therapy None None None Conventional None
Add-on therapy ERA Placebo ERA Placebo ERA Placebo Pr (iv ep) Conventional PDE5i Placebo
Treatment dose 62.5 mg bosentan twice daily, increased to 125 mg twice daily after 4 weeks. 62.5 mg bosentan twice daily, increased to either 125 mg or 250 mg twice daily after 4 weeks. 62.5 mg bosentan twice daily, increased to 125 mg twice daily after 4 weeks. mean dose of intravenous epoprostenol 9.2 ng/kg/min 80 mg sildenafil orally 3 times daily
Patients at end of trial 21 11 144 69 60 62 41 40 71 70
Duration 12 weeks 16 weeks 18 weeks 12 weeks 12 weeks
Change 6MWD 70 (23.4) −6 (50.5) 36 (6.5) −8 (9.5) 23 (9.3) −6.5 (9.2) 32 (24.8) −15 (33) 50 (9) 2 (7)
Baseline 6MWD 360 (18.8) 355 (24.7) 330 (6.2) 344 (9.1) 337 (10.1) 321 (10.8) 316 (18) 272 (23.0) 339 (9.4) 344 (9.4)
Age 52.2 47.4 48.7 47.2 49 53 40 40 48 49
Sex (% male) 0.19 0 0.21 0.22 0.22 0.24 0.24 0.3 0.21 0.19
STATUS 3 3 3.097222 3.057971 2.65 2.693548 3.243902 3.275 2.619718 2.557143
PVR 896 942 1014 880 880 880 1280 1280 918 1051
  1. *ERA are endothelin receptor antagonists, PDE5i are phosphodiesterase 5 inhibitors, Pr are prostacyclin analogues. iv ep is intravenous epoprostenol.